Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05389319Phase 1Suspended

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

Role: collaborator

NCT02529904Phase 2Completed

ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults

Role: collaborator

NCT02523287Phase 4Completed

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Role: collaborator

All 3 trials loaded